Avalo Therapeutics
AVTX
71 hedge funds and large institutions have $176M invested in Avalo Therapeutics in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 11 closing their positions.
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
11% more funds holding
Funds holding: 64 → 71 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.02% → 0.03% (+0%)
8% less call options, than puts
Call options by funds: $210K | Put options by funds: $229K
21% less capital invested
Capital invested by funds: $223M → $176M (-$47.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$16.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.2M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
+$2.67M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.39M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBF
Sara-Bay Financial
Sarasota,
Florida
|
-$5.18M |
| 2 |
Two Sigma Advisers
New York
|
-$1.18M |
| 3 |
Two Sigma Investments
New York
|
-$1.13M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$503K |
| 5 |
Morgan Stanley
New York
|
-$340K |
AVTX Hedge Fund Activity: Q3 2021 in Review
71 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2021, worth a combined $176M — down 21% from $223M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AVTX positions and 11 closed out — a net gain of 7 holders — while 19 added to existing stakes and 16 trimmed.
The largest buyer was Armistice Capital, adding an estimated $16.6M. The largest seller was Sara-Bay Financial, exiting entirely with an estimated $5.18M sold.
- 71 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2021, up from 64 in Q2 2021.
- Funds reported $176M of Avalo Therapeutics stock for Q3 2021, down 21% quarter-over-quarter.
- 18 funds opened new Avalo Therapeutics positions in Q3 2021 and 11 closed out, a net change of +7 holders.
- The largest Avalo Therapeutics buyer in Q3 2021 was Armistice Capital, an estimated $16.6M added.
- The largest Avalo Therapeutics seller in Q3 2021 was Sara-Bay Financial, an estimated $5.18M sold.
Based on aggregated 13F filings for Q3 2021.